Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.

A user is experiencing hair regrowth after treating vitamin D, B12, and B9 deficiencies, noticing some improvement after 9 months. They are unsure if further improvement will occur or if they have reached the end of progress, with a possibility of androgenetic alopecia (AGA) being suggested.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.

The user is experiencing breast tenderness and lumps after three weeks on 0.5 mg oral finasteride, a common side effect. They also report mild brain fog and fatigue but are less concerned about these symptoms.

The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.

A user with high pre-finasteride estrogen levels is asking if they need to normalize their hormone levels before starting finasteride and whether they should postpone dermarolling until they begin finasteride. The user is 21.5 years old.

Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.

A user's experience with a hair transplant, as well as the use of finasteride to maintain results.

A user beginning to take Pyrilutamide as a treatment for their hair loss, and other users sharing their experiences with the drug or similar treatments such as Minoxidil, Finasteride, and RU58841.

A user shared their one-year progress on dutasteride, noting fuller hair but persistent thinning at the crown. They sought advice on whether to resume minoxidil and in which form, while others inquired about their choice of dutasteride and its effects.

The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.

The conversation is about the release date of pyrilutamide for hair loss treatment. No specific release date is provided.

The user has been using oral finasteride, topical minoxidil, and tretinoin cream for hair loss, with positive progress noted after six months. They are advised to continue their current regimen and consider additional treatments like derma rolling, while being cautious about switching to dutasteride due to potential side effects.

The user experienced significant hair regrowth using minoxidil, microneedling, and estrogen, leading to a need to tie their hair back. They attribute the success to estrogen suppressing testosterone, alongside their routine of minoxidil, microneedling, and supplements.

A 34-year-old man had a successful hair transplant in Turkey, receiving 4,400 grafts, and is now using oils, serums, and an aftercare set. The procedure cost approximately $3,500, and he feels much younger and more confident.

A 25-year-old switched from finasteride to dutasteride, experiencing significant hair regrowth and improved hair quality after 6 months, taking it three times a week. The user stopped finasteride entirely, citing dutasteride's longer half-life as more effective.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

A female user has experienced severe hair shedding since stopping birth control in late 2022, diagnosed as telogen effluvium with no signs of androgenetic alopecia. Despite healthy living and optimal bloodwork, she continues to shed hair daily but also sees significant regrowth.

OP is considering dutasteride mesotherapy for hair loss after experiencing side effects from finasteride. A user shared their experience, stating that the treatment was ineffective and costly.

A user on dutasteride for hair loss noticed hair regrowth on their head but a significant reduction in body hair growth. They plan to switch to finasteride and dutasteride and are considering testosterone replacement therapy but are concerned about its effects on hair growth.

User shared before and after photos of hair regrowth using Dutasteride 5x a week for 19 months. They experienced significant improvement and thanked others for their support.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A 21-year-old male is using a topical treatment for hair loss, including Dutasteride, Minoxidil, Tretinoin, Ketoconazole, and Hydrocortisone, along with derma rolling. He reports no side effects from the treatment and seeks feedback on its effectiveness for hair regrowth.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

Hyperbaric Oxygen Therapy (HBOT) is discussed as a potential treatment for androgenic alopecia due to its ability to reverse hypoxia and promote angiogenesis. The conversation explores its potential benefits for hair loss, though no studies have been conducted on this application yet.

The conversation discusses the use of finasteride for hair loss, with OP considering switching to dutasteride due to concerns about effectiveness. Users share experiences and concerns about side effects, including potential impacts on fertility.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

A user reported losing 150-250 hairs daily after 9 months on dutasteride, despite previously stabilizing hair loss with finasteride and minoxidil. Blood tests showed high DHT levels, and the user is unsure if they should continue the current treatment.